|
|
KPNA2 |
karyopherin subunit alpha 2 |
- CaMK IV-mediated phosphorylation of CREB
- ISG15 antiviral mechanism
- NS1 Mediated Effects on Host Pathways
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- Sensing of DNA Double Strand Breaks
- Estrogen-dependent gene expression
- SARS-CoV-1 activates/modulates innate immune responses
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
|
|
|
|
|
LRRK1 |
leucine rich repeat kinase 1 |
|
|
|
|
|
MAP3K11 |
mitogen-activated protein kinase kinase kinase 11 |
- RAF activation
- Signaling by moderate kinase activity BRAF mutants
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- CDC42 GTPase cycle
- RHOG GTPase cycle
- RHOV GTPase cycle
- Signaling downstream of RAS mutants
|
|
|
|
|
MAP3K2 |
mitogen-activated protein kinase kinase kinase 2 |
|
|
|
|
|
MAP3K21 |
mitogen-activated protein kinase kinase kinase 21 |
|
|
|
|
|
MAPK3 |
mitogen-activated protein kinase 3 |
- MAPK3 (ERK1) activation
- RAF-independent MAPK1/3 activation
- ISG15 antiviral mechanism
- Signaling by NODAL
- Spry regulation of FGF signaling
- Signaling by Activin
- Frs2-mediated activation
- ERK/MAPK targets
- ERK/MAPK targets
- ERKs are inactivated
- Regulation of actin dynamics for phagocytic cup formation
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Oncogene Induced Senescence
- FCERI mediated MAPK activation
- Regulation of HSF1-mediated heat shock response
- NCAM signaling for neurite out-growth
- RSK activation
- Signal transduction by L1
- Activation of the AP-1 family of transcription factors
- Thrombin signalling through proteinase activated receptors (PARs)
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate NADPH Oxidases
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RNA Polymerase I Promoter Opening
- Signal attenuation
- Interferon gamma signaling
- Advanced glycosylation endproduct receptor signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- ESR-mediated signaling
- RUNX2 regulates osteoblast differentiation
- Regulation of PTEN gene transcription
- Regulation of the apoptosome activity
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Suppression of apoptosis
- Signaling downstream of RAS mutants
- Signaling by MAP2K mutants
- Signaling by RAF1 mutants
- FCGR3A-mediated phagocytosis
- Nuclear events stimulated by ALK signaling in cancer
- IFNG signaling activates MAPKs
- Negative Regulation of CDH1 Gene Transcription
- NPAS4 regulates expression of target genes
- NPAS4 regulates expression of target genes
- Growth hormone receptor signaling
- Signaling by LTK in cancer
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
- Sulindac
- Acetylsalicylic acid
- Minocycline
- Arsenic trioxide
- Colforsin
- Purvalanol
- 5-iodotubercidin
- Seliciclib
- Cholecystokinin
- Ulixertinib
|
|
|
|
MAPT |
microtubule associated protein tau |
- Caspase-mediated cleavage of cytoskeletal proteins
|
- Lansoprazole
- Astemizole
- Paclitaxel
- Docetaxel
- Flortaucipir F-18
|
- Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
|
|
|
MCF2 |
MCF.2 cell line derived transforming sequence |
- Axonal growth inhibition (RHOA activation)
- NRAGE signals death through JNK
- G alpha (12/13) signalling events
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOG GTPase cycle
- RAC3 GTPase cycle
|
|
|
|
|
METTL14 |
methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit |
- Processing of Capped Intron-Containing Pre-mRNA
|
|
|
|
|
MFHAS1 |
multifunctional ROCO family signaling regulator 1 |
|
|
|
|
|
MITF |
melanocyte inducing transcription factor |
- SUMOylation of transcription factors
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
|
- Malignant melanoma
- Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA)
- Waardenburg syndrome (WS)
|
|
|
MPP1 |
MAGUK p55 scaffold protein 1 |
- Sensory processing of sound by outer hair cells of the cochlea
|
|
|
|
|
MST1R |
macrophage stimulating 1 receptor |
|
|
|
|
|
MYOCD |
myocardin |
|
|
|
|
|
NOS1 |
nitric oxide synthase 1 |
- ROS and RNS production in phagocytes
- Nitric oxide stimulates guanylate cyclase
- Ion homeostasis
|
- Citrulline
- Donepezil
- Ketamine
- L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide
- Formic acid
- 3-Bromo-7-Nitroindazole
- N-{(4S)-4-Amino-5-[(2-aminoethyl)amino]pentyl}-N'-nitroguanidine
- N-[3-(aminomethyl)benzyl]acetamidine
- L-N(omega)-nitroarginine-(4R)-amino-L-proline amide
- 1-hydroxy-2-isopropylguanidine
- 7-Nitroindazole
- N-omega-propyl-L-arginine
- 2-butyl-1-hydroxyguanidine
- S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
- N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine
- Flavin adenine dinucleotide
- Flavin mononucleotide
- N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide
- Nicotinamide adenine dinucleotide phosphate
- S-Ethyl-N-Phenyl-Isothiourea
- [(1S)-4-(1-Aminobutylideneamino)-1-carboxybutyl]azanium
- 5-N-Allyl-arginine
- Nitroarginine
- NXN-188
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine
- Methylene blue
|
|
|
|
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
- Regulation of ornithine decarboxylase (ODC)
- NFE2L2 regulating anti-oxidant/detoxification enzymes
|
- Menadione
- Dicoumarol
- Duroquinone
- 3-Hydroxymethyl-5-Aziridinyl-1methyl-2-[1h-Indole-4,7-Dione]-Propanol
- ES-936
- Cibacron Blue
- Flavin adenine dinucleotide
- 5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione
- RH-1
- Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]
- 3-(HYDROXYMETHYL)-1-METHYL-5-(2-METHYLAZIRIDIN-1-YL)-2-PHENYL-1H-INDOLE-4,7-DIONE
- Cannabidiol
|
|
|
|
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- SUMOylation of intracellular receptors
- PTK6 Expression
- Regulation of RUNX2 expression and activity
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Potential therapeutics for SARS
- Regulation of NPAS4 gene transcription
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol acetate
- Levonorgestrel
- Beclomethasone dipropionate
- Progesterone
- Spironolactone
- Betamethasone
- Desoximetasone
- Fluticasone propionate
- Fluocinolone acetonide
- Ulobetasol
- Triamcinolone
- Prednisone
- Flumethasone
- Fludrocortisone
- Norethisterone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol etabonate
- Rimexolone
- Methylprednisolone
- Clobetasol propionate
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Drospirenone
- Ciclesonide
- Hexane-1,6-Diol
- Aldosterone
- ORG-34517
- Difluprednate
- Ulipristal
- Fluticasone furoate
- Tixocortol
- Difluocortolone
- Gestrinone
- Deflazacort
- Onapristone
- Cortivazol
- Clobetasone
- Fluticasone
- Mometasone furoate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Segesterone acetate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
- Prednisolone acetate
|
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|
|
|
OLFM3 |
olfactomedin 3 |
|
|
|
|
|
OTUD3 |
OTU deubiquitinase 3 |
- Ovarian tumor domain proteases
- Regulation of PTEN stability and activity
|
|
|
|
|
PA2G4 |
proliferation-associated 2G4 |
|
|
|